Key result
A combination of three clinical joint symptoms with serum survivin, RA-specific antibodies, and female gender over 50 years predicted the transition from arthralgia to rheumatoid arthritis with an AUC of 0.768 and a positive predictive value of 55.2%.
Why the study?
Does combining serum survivin with clinical symptoms improve the prediction of transition from arthralgia to rheumatoid arthritis?
Cohort (n=1,743)
Single-blind
No
Does combining serum survivin with clinical symptoms improve the prediction of transition from arthralgia to rheumatoid arthritis?
Combining serum survivin measurement with specific clinical joint symptoms significantly improves the prediction of imminent rheumatoid arthritis in patients presenting with unexplained arthralgia.
Answers are grounded in this paper and cite their sources.
May support RA risk stratification in arthralgia; hypothesis-generating and requires prospective validation before clinical use.
Background: Arthralgia often predates development of rheumatoid arthritis (RA). A set of clinical joint symptoms assisting recognition of patients during their transition from arthralgia to RA, has been recently proposed. Aim: To combine clinical and serological markers aiming to improve recognition of imminent rheumatoid arthritis (RA) among patients with arthralgia. Methods: The total of 1743 first-visit patients attending the rheumatology ward in Gothenburg for joint symptoms were identified during 12 consecutive months. Among those, 63 patients were classified as RA, 73 had undifferentiated arthritis and 180 had unexplained arthralgia. New cases of RA, which developed during the prospective follow-up of 48 months, comprised the preclinical (pre-)RA group. The set of joint symptoms was applied to the first-visit records aiming to distinguish a) patients with arthralgia and arthritis, b) patients with pre-RA, who later develop the disease, and the receiver operating characteristics curves were constructed. To improve specificity, the model was limited to the symptoms with the odds ratio >2.0 between the arthralgia and pre-RA group and enriched with information about RA-specific antibodies and survivin in serum. Results: The proposed set of clinical symptoms distinguished the arthralgia patients from RA and from pre-RA. A combination of symptoms in several small joint areas, increasing number of joints with symptoms, and patient’s experience of swelling in small hand joints at the first visit was sufficient to identify pre-RA cases with 92% sensitivity. Presence of survivin in serum showed strong association with clinical joint symptoms. Grouping those symptoms with information about age, gender and serum levels of survivin or autoantibodies in the final algorithm allowed reaching 50% specificity and 55% of positive prediction for transition from arthralgia to RA. Conclusion: Clinical and serological parameters in combination aid recognition of imminent RA among arthralgia patients with appropriate sensitivity.
No takes yet. Share an insight, caveat, or question.
Erlandsson et al. (2018) conducted a cohort in Arthralgia (n=1,743). Clinical symptoms combined with serum survivin, RA-specific antibodies, and demographic factors vs. Absence of predictive parameters was evaluated on Development of polyarthritis meeting ≥6 points of the EULAR/ACR Criteria 2010 (transition to RA) (AUC 0.768, 95% CI 0.674-0.860, p=<0.001). A combination of three clinical joint symptoms with serum survivin, RA-specific antibodies, and female gender over 50 years predicted the transition from arthralgia to rheumatoid arthritis with an AUC of 0.768 and a positive predictive value of 55.2%.
Synapse has enriched 10 related papers. Consider them for comparative context: